menu
    • menu
    [{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Influenza A (H5N1) monovalent vaccine, adjuvanted","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent influenza vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Cell-based Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Seqirus","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"Seqirus","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Seqirus \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ BARDA"},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"sa-mRNA Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ Not Applicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"Seqirus","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Seqirus"}]

    Find Clinical Drug Pipeline Developments & Deals by Seqirus

    Menu

    Seqirus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : ARS Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ARS Submits Response for Neffy Epinephrine Nasal Spray to EMA and Licenses to CSL Seqirus

                            Details : CSL Seqirus will apply for regulatory and pricing and reimbursement approvals, and will be responsible for commercializing neffy (epinephrine nasal spray) across Australia and New Zealand.

                            Brand Name : Neffy

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : ARS Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Amarin

                            Deal Size : $12.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA (icosape...

                            Details : Under the terms of the agreement, Amarin will license exclusive rights to Vazkepa (icosapent ethyl) to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.

                            Brand Name : Vazkepa

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 28, 2023

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Amarin

                            Deal Size : $12.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : H5N8 A/Astrakhan Virus Vaccine,Squalene API

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : BARDA

                            Deal Size : $30.1 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemi...

                            Details : Under the terms of the agreement, CSL Seqirus will deliver an H5N8 A/Astrakhan virus vaccine candidate and will then sponsor a subsequent Phase 2 clinical trial to evaluate the candidate along with CSL Seqirus' proprietary adjuvant MF59®.

                            Brand Name : H5N8 A/Astrakhan

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 06, 2022

                            Lead Product(s) : H5N8 A/Astrakhan Virus Vaccine,Squalene API

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : BARDA

                            Deal Size : $30.1 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : sa-mRNA Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidat...

                            Details : The results demonstrate that the A(H5N1) sa-mRNA influenza vaccine candidate induced an anti-HA and anti-NA neutralizing response raised by sa-mRNA influenza vaccines at a dose as low as 0.01 µg in mice and also induced HA-specific CD4+ T cells.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : sa-mRNA Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Influenza A (H5N1) Monovalent Vaccine, Adjuvanted

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Biomedical Advanced Research and Development Authority

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response

                            Details : Supply of AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A (H5N1) in the event of a pandemic.

                            Brand Name : Audenz

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 25, 2022

                            Lead Product(s) : Influenza A (H5N1) Monovalent Vaccine, Adjuvanted

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Biomedical Advanced Research and Development Authority

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine...

                            Details : Flucelvax Quadrivalent is cell-based quadrivalent seasonal influenza vaccine (QIVc) that helps protect people aged 6 months and older from the flu.

                            Brand Name : Flucelvax Quadrivalent

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 19, 2021

                            Lead Product(s) : Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication t...

                            Details : FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine, for expanded age indication for children as young as six months old. FLUCELVAX QUADRIVALENT utilizes a cell-based influenza vaccine manufacturing proce...

                            Brand Name : Flucelvax Quadrivalent

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 15, 2021

                            Lead Product(s) : Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Infl...

                            Details : FLUCELVAX QUADRIVALENT is a vaccine that helps protect people aged 2 and older from the flu. Vaccination with FLUCELVAX QUADRIVALENT may not protect all people who receive the vaccine.

                            Brand Name : Flucelvax Quadrivalent

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 14, 2021

                            Lead Product(s) : Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cell-based Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Inf...

                            Details : QIVc and aTIV demonstrated effectiveness in preventing hospitalizations related to influenza, during both the broader influenza season and the high activity period. Flucelvax Quadrivalent is a vaccine that helps protect people aged 2 and older from the f...

                            Brand Name : Flucelvax Quadrivalent

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 29, 2021

                            Lead Product(s) : Cell-based Quadrivalent Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Seqirus

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Athenex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Athenex Announces Additional License Agreement for Tirbanibulin

                            Details : Under the terms of the agreements, Seqirus will have an exclusive license to commercialize tirbanibulin in Australia and New Zealand, and AVIR will have an exclusive license to commercialize tirbanibulin in Canada.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 26, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Athenex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth